Enroll additional patients in AMT-130 Phase I/II clinical trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 25 Oct 2021
- Due
- 31 Dec 2021
- Delivered
- 31 Dec 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“the Company expects to enroll additional patients before the end of 2021.”
What we found
Evidence strength A What the grades mean
The company successfully enrolled additional patients in the AMT-130 Phase I/II clinical trial by the end of 2021, reaching a total of 19 patients enrolled by December 31, 2021.
-
A uniQure N.V. 10-K filed 2022-02-25
“As of December 31, 2021, 19 patients have been enrolled in the clinical trial to date, including nine of 16 in the high-dose cohort.” ✓ confirmed on the page
Market reaction: the shares moved +8.6% against the S&P 500 over the three sessions around the disclosure (24 Feb 2022 to 1 Mar 2022). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Enroll
- Deliverable
- additional patients in AMT-130 trial
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
- Conditional
- Yes: assuming a positive recommendation from the DSMB
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-QURE-001782 · Corrections policy